Glutathione and Platinum Drug Sensitivity in Ovarian Cancer
Author Information
Author(s): P. Mistry, L.R. Kelland, G. Abel, S. Sidhar, K.R. Harrap
Primary Institution: The Institute of Cancer Research
Hypothesis
The study investigates the role of glutathione and glutathione-S-transferase in modulating the cytotoxicity of platinum drugs in ovarian carcinoma cell lines.
Conclusion
The study found that higher levels of glutathione correlate with reduced sensitivity to platinum drugs in ovarian cancer cell lines.
Supporting Evidence
- Intracellular glutathione concentration showed a significant correlation with IC50 values for cisplatin, carboplatin, and CHIP.
- Depletion of cellular GSH enhanced the cytotoxicity of platinum drugs in both sensitive and resistant cell lines.
- The study established a range of human ovarian carcinoma cell lines that reflect clinical responses to platinum drugs.
Takeaway
This study looked at how a substance called glutathione affects how well certain cancer drugs work on ovarian cancer cells. More glutathione means the drugs don't work as well.
Methodology
The study evaluated the cytotoxicity of four platinum drugs and melphalan in eight human ovarian carcinoma cell lines, measuring glutathione levels and GST activity.
Limitations
The study did not explore the specific isoenzymes of GST that may affect drug sensitivity.
Participant Demographics
Cell lines were established from solid and ascitic tumors from pretreated and untreated patients.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website